Ryufin

SALUS, Ljubljana, d.d.

Slovenia · SI0031110453 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2024. Each line says what it is based on.

Is it growing?Fair
Revenue +8.2% in the year to Dec 31, 2024, on the year before.
Is it a good business?Good
It earned 15% on its shareholders' equity in the year to Dec 31, 2024.
Is it safe?Fair
Equity is 39% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2024, consolidated, in EUR.

€649M

revenue

2.6%

operating margin

€13M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2021Dec 2022Dec 2023Dec 2024
Revenue€458M€496M€599M€649M
Operating profit€15M€16M€13M€17M
Net profit to shareholdersn/an/a€10M€13M
Dividend per sharen/a€65.00n/a€70.00
Cash from operations€23M€12M€22M€12M
Cash€18M€19M€23M€17M
Total assets€169M€175M€216M€217M
Equity€67M€74M€79M€85M

What they do

In the company's own words, from the annual report.

Skupina SALUS predstavlja vitalni člen v oskrbi z zdravili, prehranskimi dodatki, medicinskimi pripomočki in kakovostnimi ter inovativnimi storitvami, ki prinašajo zdravje in dobro počutje ljudi, saj je specializirana za ponudbo celostne storitve distribucije, promocije in aktivne prodaje ter spremljajočih storitev, da zdravilo ali medicinski pripomoček pride na trg. Regionalno je prisotna na trgih srednje in vzhodne Evrope, in sicer s svojimi družbami (na območju Slovenije, Hrvaške, Srbije, Bosne in Hercegovine, Črne Gore, Severne Makedonije, Albanije in Litve) ali preko lokalnih partnerjev (na območju Kosova, Romunije in Bolgarije). Dejavnosti družb Skupine SALUS lahko v grobem razdelimo na tri sklope: veleprodajo, storitve in zastopstva ter maloprodajo, pri čemer nekatere družbe v Skupini pokrivajo več zgoraj navedenih dejavnosti poslovanja, medtem ko so druge usmerjene na samo nekate

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.